TY - JOUR
T1 - Molecular imaging of prostate cancer
T2 - Review of imaging agents, modalities, and current status
AU - Quesada-Olarte, J. M.
AU - Allaf, M. E.
AU - Alvarez-Maestro, M.
AU - Martínez-Piñeiro, L.
N1 - Publisher Copyright:
© 2020 AEU
PY - 2020/7/1
Y1 - 2020/7/1
N2 - Introduction: The clinical course of Prostate cancer (PCa) are markedly diverse, ranging from indolent to highly aggressive disseminated disease. Molecular imaging techniques are playing an increasing role in early PCa detection, staging and disease recurrence. There are some molecular imaging modalities, radiotracers agents and its performance are important in current clinical practice PCa. Objective: This review summarizes the latest information regarding molecular imaging of PCa and is designed to assist urologists with ordering and interpreting these modalities and different radiotracers for different patients. Evidence acquisition: A PubMed-based literature search was conducted up to September 2019. We selected the most recent and relevant original articles, metanalysis and reviews that have provided relevant information to guide molecular imaging modalities and radiotracers use. Evidence synthesis: In this review, we discuss 3 main molecular imaging modalities and 7 radiotracer technologies available. Conclusions: The use molecular imaging modalities and radiotracers has a unique role in biochemical recurrence and diagnosis of ganglionar and bone progression of PCa. In the present time, no one of these molecular imaging modalities can be recommended over the classical work-up of abdominopelvic CT scan and bone scan, and large-scale and multi-institutional studies are required to validate the efficacy and cost utility of these new technologies.
AB - Introduction: The clinical course of Prostate cancer (PCa) are markedly diverse, ranging from indolent to highly aggressive disseminated disease. Molecular imaging techniques are playing an increasing role in early PCa detection, staging and disease recurrence. There are some molecular imaging modalities, radiotracers agents and its performance are important in current clinical practice PCa. Objective: This review summarizes the latest information regarding molecular imaging of PCa and is designed to assist urologists with ordering and interpreting these modalities and different radiotracers for different patients. Evidence acquisition: A PubMed-based literature search was conducted up to September 2019. We selected the most recent and relevant original articles, metanalysis and reviews that have provided relevant information to guide molecular imaging modalities and radiotracers use. Evidence synthesis: In this review, we discuss 3 main molecular imaging modalities and 7 radiotracer technologies available. Conclusions: The use molecular imaging modalities and radiotracers has a unique role in biochemical recurrence and diagnosis of ganglionar and bone progression of PCa. In the present time, no one of these molecular imaging modalities can be recommended over the classical work-up of abdominopelvic CT scan and bone scan, and large-scale and multi-institutional studies are required to validate the efficacy and cost utility of these new technologies.
KW - Molecular imaging modalities
KW - Prostate cancer
KW - Radiotracers agents
UR - http://www.scopus.com/inward/record.url?scp=85088221658&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85088221658&partnerID=8YFLogxK
U2 - 10.1016/j.acuro.2019.12.003
DO - 10.1016/j.acuro.2019.12.003
M3 - Review article
C2 - 32709428
AN - SCOPUS:85088221658
SN - 0210-4806
VL - 44
SP - 386
EP - 399
JO - Actas urologicas espanolas
JF - Actas urologicas espanolas
IS - 6
ER -